Biomanufacturing for both traditional biologics and new modalities, such as cell and gene therapies, continues to be an active area of investment for CDMOs/CMOS. Some of...
Successfully managing the drug substance manufacturing of Antibody-Drug Conjugates (ADCs) requires a sophisticated understanding of the technological development process...
US scientific equipment manufacturer Thermo Fisher Scientific and China-based CDMO Innoforce have formed a joint venture to own and operate a new pharma services facility...
25.02.2019
- Catalent appointed Kay Schmidt as senior vice president, Technical Operations. In this new role, Schmidt will report to Alessandro Maselli, who earlier this month was appointed as...
10.01.2019
- US-based Catalent is investing $200 million in its biologics business to expand drug substance manufacturing capacity and fill/finish capabilities at its sites in Madison...
30.04.2018
- US drugmaker Catalent announced key organizational changes within its biologics business. Tedd Green, former president of Cook Pharmica, has been appointed as senior vice president...
30.03.2018
- With a market value of $62 billion in 2016, the contract development and manufacturing organization (CDMO) industry has a compound annual growth rate (CAGR) of 6-7 %, according to...
18.10.2017
- As generics pricing pressure increases, Swiss drugmaker Novartis said it will close a US plant at Broomfield, Colorado, owned by its Sandoz subsidiary and employing 450 people. It...
